Company History

Our strategic vision is rooted in the sound financial foundations, sustainable innovation, and long-term mentality of our parent company JSR Corporation – a multinational advanced materials and solutions company with a long track record of success and innovation. This vision is infused with JSR’s rich culture of patience, thoroughness, and commitment to investing in durable, sustainable opportunities instead of short-term transactions.

JSR Corporation created JSR Life Sciences to realize the significant growth engine that the life sciences business can provide for long-term future growth. Through the acquisition of affiliate companies, our life sciences division has become a leading source of life sciences research products and services worldwide.

Expansion in Life Sciences Fields

By converging JSRs leading position in materials innovation with JSR Life Sciences best-in-class companies, the Company is in a unique position to deliver on the promise of digital health by making medicines more personalized and precise.

2012

JSR Life Sciences Corporation

In 2012, JSR established new company called
“JSR Life Sciences Corporation” in acceleration of life sciences business

2015

Amsphere A3

JSR and JSR Life Sciences developed Amsphere™ A3, a next generation protein A chromatography resin

KBI Biopharma

JSR jointly acquired KBI Biopharma, Inc., a contract developer and manufacturers of biopharmaceuticals in the United States

2016

MBLI

MBLI becomes a consolidated subsidiary of JSR

2017

Selexis SA

Selexis SA becomes consolidated subsidiary of JSR

JKiC

JSR-Keio University Medical and Chemical Innovation Center (JKiC) is founded

2018

Crown Bioscience

Crown Bioscience International becomes consolidated subsidiary of JSR

2019

JSR Life Sciences, LLC

Establishes US Headquarters for biotechnology and life sciences focused businesses under
the name JSR Life Sciences, LLC effective April 1, 2019

2021

Launch of JSR Life Sciences Venture Fund

As part of a continued effort to identify and accelerate novel therapies and innovative technologies, JSR established a corporate venture fund. The fund focuses on early stage, innovative biotech companies developing transformative disease therapies and diagnostic tools and breakthrough discovery and development platforms.

2022

Similis Bio

JSR Life Sciences launches Similis Bio, a biosimilar development offering.

2023

KBI Biopharma & Selexis Consolidate

JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as one Organization, Providing Seamless Experience for Partners